Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial-Reference-Cited by-同舟云学术

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial

Published:2017-07-19 Issue:1 Volume:18 Page:
ISSN:1471-2474
Container-title:BMC Musculoskeletal Disorders
language:en
Short-container-title:BMC Musculoskelet Disord

Author:

Wijesinghe Harindu,Galappatthy Priyadharshini,de Silva Rajiva,Seneviratne Suranjith L.,Saravanamuttu Ushagowry,Udagama Preethi,Hart Melanie,Kelleher Peter,Senerath Upul,Fernandopulle Rohini,Weerasekera Lilani P.,Wijayaratne Lalith S.

Funder

The local agents of rituximab provided the study medications, some laboratory reagents and a study coordinator. The local agents of leflunomide provided study medications and matching placebo tablets

Publisher

Springer Science and Business Media LLC

Subject

Orthopedics and Sports Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/s12891-017-1673-3.pdf

Reference28 articles.

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.

2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39.

3. Administration USFDA Drug Safety Communication: new boxed warning for severe liver injury with arthritis drug Arava (leflunomide). 2010. www.fda.gov/Drugs/DrugSafety/ucm218679.html (accessed 15 May 2015).

4. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459–66.

5. St. Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the Mechanism of the Combination of Methotrexate and Leflunomide in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology, Molecular Docking, and in vitro Experimental Verification;Combinatorial Chemistry & High Throughput Screening;2024-06-20

2. Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023;Reumatología Clínica;2024-05

3. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023;Reumatología Clínica (English Edition);2024-05

4. Immune hallmarks of rheumatoid arthritis management: A brief review;Cytokine;2022-10

5. Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis;Medicine;2022-08-12